Asian Bamboo AG / Key word(s): Preliminary Results 07.08.2014 16:14 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Asian Bamboo announces preliminary Q1-Q2 2014 results and adjusts its guidance for the year Hamburg, 7 August 2014 - Asian Bamboo AG ("Asian Bamboo", "the Company", ISIN: DE000A0M6M79, ticker symbol: "5AB", ADR ticker symbol "ASIBY"), announces the following preliminary results for the period Q1-Q2 2014 (percentage numbers are year-on-year comparisons): - Revenue decreased 22% to EUR 10.8 million* (Q1-Q2 2013: EUR 13.7 million*) - Gross profit including FVBA-changes** increased 204% to EUR 5 million (Q1-Q2 2013: EUR 1.6 million), equivalent to a gross profit margin including FVBA-changes of 46% (Q1-Q2 2013: restated: 12%) - Net profit of EUR 8.1 million (Q1-Q2 2013 restated: net loss of EUR 2.2 million) - Operating cash flow before movements in working capital was EUR 1.3 million (Q1-Q2 2013: EUR 4.5 million) - Net cash generated from operating activities was positive EUR 4.2 million (Q1-Q2 2013: negative EUR 4 million) - Cash and cash equivalents of EUR 26 million (31 December 2013: EUR 28.5 million) * Revenue numbers do not include sales of bamboo fibre as it is treated as a discontinued operation **FVBA is an abbreviation for gains/(losses) arising from changes in the fair value less estimated costs to sell of biological assets In the first half of the year the performance remained unsatisfactory due to the structural issues the plantation business is facing. In addition, the spring bamboo shoot harvest was negatively affected by heavy rain during the key harvesting weeks, which also had a negative impact on the amount of dried bamboo shoots available for harvest. The Management Board continued to exercise stringent cost control and the provisions made for onerous plantation lease contracts have lowered the total amortisation costs. In addition, on 22 April the Company announced an agreement to give up the rights to certain plantations, which resulted in an accounting gain of EUR 6.9 million in Q2. Most importantly, the business continued to be net operating cash flow positive. The Management Board expects the overall operating situation for the plantation business to remain challenging. Due to the negative impact of weather in Q2 and the bleak outlook, the Management Board lowers the revenue forecasts to around EUR 23 million. However, at the same time the Management Board maintains the net operating cash flow forecast at EUR 3 million and expects a slightly positive net profit in FY 2014. For enquiries, please contact: Asian Bamboo AG: Peter Sjovall +852-9385 3868 Chief Financial Officer peter.sjovall@asian-bamboo.com Anja Holst +49-(0)40 37644 798 Investor Relations Director anja.holst@asian-bamboo.com About Asian Bamboo AG: Asian Bamboo is a leading integrated company in the bamboo industry. The Company currently owns long-term leasing rights for 40 bamboo plantations with a total size of 50,338 hectares (ha). It is planning to diversify its business into property development. As a National Key Flagship Enterprise, Asian Bamboo is at the forefront of developing the agriculture industry in China. Asian Bamboo has obtained organic food accreditations in China, Japan, Europe and the United States in addition to its HACCP and ISO9001 certifications. Its plantation management has received GLOBALGAP (Global Good Agriculture Practices) certification from the Swiss-based company SGS. Since 16 November 2007, Asian Bamboo has been listed on the Prime Standard of the Frankfurt Stock Exchange under the ticker symbol "5AB". In addition, the stock is traded as an ADR under the ticker symbol "ASIBY". The Company's financial statements are audited by Deloitte and its registered office is located in Hamburg, Germany. For more information about Asian Bamboo, please visit the Asian Bamboo website at www.asian-bamboo.com or www.asian-bamboo.de Disclaimer: This release is for information only and does not constitute an offer to sell, purchase, exchange or transfer any securities or a solicitation of any such offer in the United States or any other jurisdiction. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the 'Securities Act') and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. Neither Asian Bamboo AG ("Asian Bamboo") nor any other participant in the transactions described herein intends to register any securities under the Securities Act or with any securities regulatory authority of any state or other jurisdiction in the United States in connection with the proposals described in this announcement. The shares may not be offered to the public in any jurisdiction in circumstances which would require the preparation or registration of any prospectus or offering document relating to the shares in such jurisdiction. No action has been taken by Asian Bamboo or any of their affiliates that would permit an offering of the shares or possession or distribution of this announcement or any other offering or publicity material relating to such securities in any jurisdiction where action for that purpose is required. As far as this release contains forward-looking statements with respect to the business, financial condition and results of operations of Asian Bamboo, these statements are based on current expectations or beliefs of Asian Bamboo's management. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or performance of the Company to differ materially from those reflected in such forward-looking statements. Apart from other factors not mentioned here, differences could occur as a result of changes in the overall economic situation and the competitive environment - especially in the core business segments and markets of Asian Bamboo. Also, the development of the financial markets and changes in national as well as international provisions, particularly in the field of tax legislation and financial reporting standards, could have an effect. Terrorist attacks and their consequences could increase the likelihood and the extent of differences. Asian Bamboo undertakes no obligation to publicly release any revisions or updates to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. 07.08.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Asian Bamboo AG Stadthausbrücke 1-3 20355 Hamburg Germany Phone: +49 40 37644 798 Fax: +49 40 37644 500 E-mail: info@asian-bamboo.de Internet: www.asian-bamboo.de ISIN: DE000A0M6M79, DE000A0M6M79 WKN: A0M6M7, A0M6M7 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Asian Bamboo announces preliminary Q1-Q2 2014
Top 10 Most Recent News Articles
D-Wave Quantum Hit with Securities Fraud Lawsuit
A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...
Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact
A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...
Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026
A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...
Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives
Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...
Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data
Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...
Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path
New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...
Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake
Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...
Continue ReadingTop 5 Most Recently Viewed Articles
HD Hyundai Sparks Fusion Hopes with ITER Milestone
Hold on to Your Hard Hats, Fusion Milestone Achieved Look who's making waves in the world of nuclear fusion. HD Hyundai Heavy Industries has hit a crucial benchmark in the ITER nuclear fusion project. This ain't your run-of-the-mill accomplishment, folks. We're talking about completing the assembly of some of the most complex and intricately designed machinery known to...
Continue Reading
ChemoMetec Boosts Financial Outlook with Anticipated Growth
ChemoMetec Boosts Financial Outlook Amid Growing Interest ChemoMetec is excited to announce an upgrade in its financial guidance as the company sees a growing demand for its pioneering technologies, particularly the highly regarded XcytoMatic platform. This surge in interest bodes well for the company's revenue and profit, reflecting a positive trajectory as it approaches...
Continue Reading
GDS Holdings Completes Successful C-REIT IPO on Shanghai Exchange
GDS Holdings Limited Celebrates C-REIT IPO Success GDS Holdings Limited, known as GDS, is thrilled to announce that it has successfully completed its initial public offering of its China REIT, or C-REIT, on the Shanghai Stock Exchange. This milestone marks an exciting moment for the company and its stakeholders as market interest surpassed expectations. Highlighting the...
Continue Reading
Innovative E-Waste Solutions from Techbros Redefine Recycling
AI-Driven E-Waste Innovation from Techbros In a remarkable leap towards sustainability and innovative technology, Techbros Electronic Recycling proudly announces the launch of the Southwest's first fully integrated AI-driven IT asset disposition (ITAD) and e-waste processing facility. This state-of-the-art facility exemplifies the future of electronics recycling by...
Continue Reading
SageSure Welcomes Insurance Veteran Peter Hearn to Board
SageSure Welcomes New Board Member SageSure, one of the largest managing general underwriters that focus on markets exposed to catastrophe risks, has taken a significant step by appointing Peter Hearn to its Board of Managers. This strategic move is anticipated to bolster the company’s leadership and industry insights. Peter Hearn's Impressive Background Peter Hearn...
Continue Reading